This strategic move brings stability to Embecta, addressing challenges faced since its spin-off from Becton Dickinson & Co.

The acquisition brings in the Aidaptus auto-injector platform and related intellectual property.

Alerje founder Javier Evelyn’s mobile auto-injector platform was recently acquired by SemPresto.

Physicians identified key improvements for adrenaline auto-injectors, including longer shelf life and easier use, improving anaphylaxis care. Learn more.

The acquisition positions Embecta to enter the fast-growing drug-delivery device market and accelerate its shift to a broader ...

Acquisition will position embecta to participate in the rapidly expanding market for drug-delivery devices supporting generic ...

This reflects the confidence pharmaceutical innovators place in Pyramid’s expanded state-of-the-art facility to deliver ...

Zydus Lifesciences Limited (including its subsidiaries, hereafter referred to as “Zydus”), an innovation-led global lifesciences company, has launched Semaglutide Injection under the brand names – ...

Embecta Corp. ("Embecta") (Nasdaq: EMBC), a global leader in diabetes care technology, today announced that it has entered into a definitive agreement ...

The planned purchase would allow Embecta to serve patients outside of diabetes care.

Embecta hits multi-year lows on GLP-1 fears, but offers 6%+ yield and deep value. Read the latest analysis on the stock and ...

Embecta (Nasdaq:EMBC) announced today that it entered into a definitive agreement to acquire Owen Mumford Holdings Limited.